GlobalData’s detailed strategic reports on the MFN executive order and on the GENEROUS model examined how some of the known ...

After signing a drug pricing deal with the White House, J&J will now offer some of its branded medicines at discounted rates ...

CDMOs are re-evaluating a reliance on China and increasingly turning to nearshoring and friendshoring for supply chain ...

Sino Biological launched its Center for Bioprocessing (C4B) at the heart of the Texas Medical Center hub in Houston, Texas, ...

Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector ...

Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...

With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...

Santhera Pharmaceuticals has entered into an exclusive licensing agreement with Nxera Pharma for Agamree to treat DMD in ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Mikron Automation and Denver-based Confluent Development have announced the expansion of Mikron Automation’s US headquarters ...

Octapharma has received approval from the US FDA for a new 2-g formulation of Fibryga for use in patients with AFD.